

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ALTMANN ET AL.

APPLICATION NO: Not Yet Assigned

FILED: Herewith

FOR: VEGF RECEPTOR TYROSINE KINASE INHIBITORS

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


This paper is being filed within three months of the filing date of the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 10/180,289 filed June 26, 2002, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Lydia T. McNally  
Attorney for Applicants  
Reg. No. 36,214

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 430  
East Hanover, NJ 07936-1080  
(862) 778-7898

Date: April 21, 2004

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
4-30707C  
APPLICATION NO.  
Not Yet Known  
APPLICANT  
ALTMANN ET AL.  
FILING DATE  
Herewith

Group

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	3,226,394	12/28/65	Schipper			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	1,189,719	4/29/70	Great Britain			<input type="checkbox"/>	<input type="checkbox"/>
	AN	10-259176	9/29/98	Japan			<input type="checkbox"/>	<input type="checkbox"/>
	AO	56-161362	12/11/81	Japan			<input type="checkbox"/>	<input type="checkbox"/>
	AP	9-59236	3/4/97	Japan			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	EP 0 947 500 A1	10/6/99	Europe			<input type="checkbox"/>	<input type="checkbox"/>

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Japan Tobacco Inc., Chemical Abstracts, 1982: 162351, (JP 56-161362, 12/11/1981).
	AS	Inaba et al., Chemical Abstracts 129:310895, 06/04/99, (JP 10-259176, 09/29/1998)
	AT	Augustin, TiPS, Vol.19, "Antiangiogenic tumour therapy: will it work?" pp. 216-222, (June 1998).

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
4-30707C  
APPLICATION NO.  
Not Yet Known  
APPLICANT  
ALTMANN ET AL.  
FILING DATE  
Herewith

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BM	95/25723	9/28/95	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BN	96/09294	3/28/96	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BO	96/41795	12/27/96	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BP	98/17648	4/30/98	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BQ	99/32477	7/1/99	PCT			<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	Hisano et al., Chem. Pharm.Bull., Vol.20, No.12, "Syntheses and Pharmacological Activities of 2-Heterocyclic Substituted 4(3H)-Quinazolinone Derivatives," pp. 2575-2584, (1972).
	BS	Lüddens et al., European Journal of Pharmacology, Vol.344, "Structure – activity relationship of furosemide-derived compounds as antagonists of cerebellum-specific GABA <sub>A</sub> receptors," pp. 269-277, (1998).
	BT	Caplus, English Abstract JP9059236, Kawagoe Keiichi, 3/1997

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
4-30707C  
APPLICATION NO.  
Not Yet Known  
APPLICANT  
ALTMANN ET AL.  
FILING DATE  
Herewith

Group

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BM	99/54284	10/28/99	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BN	19830430	1/13/00	Germany			<input type="checkbox"/>	<input type="checkbox"/>
	BO	9059236	3/14/97	Japan			<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	Breier et al., Trends in Cell Biology, Vol.6, "The Role of Vascular Endothelial Growth Factor in Blood Vessel Formation," pp.454-456, (December 1996).
	BS	Mikhailitsyn et al., Chemical Abstracts, Vol. 116, 41373f, p. 771, (1992) XP-002128306
	BT	Shani et al., Pharmacology, Vol.26, "Structure Activity Correlation for Diuretic Furosemide Congeners," pp. 172-180, (1983).

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
4-30707C  
APPLICATION NO.  
Not Yet Known  
APPLICANT  
ALTMANN ET AL.  
FILING DATE  
Herewith

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BM						<input type="checkbox"/>	<input type="checkbox"/>
	BN						<input type="checkbox"/>	<input type="checkbox"/>
	BO						<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	Tiwari et al., J.Chem.Soc.Pak, Vol.4, No.2, "Visible Antifertility Compounds – Part IV: Syntheses of 2-(Phthalimido methylamino)-substituted benzanilides," pp.115-117, (1982).
	BS	Varnavas et al., Pharmazie, Vol. 51, "Anthranoyl-anthranilic acid: a template for the development of a new class of cholecystokinin receptor ligands," pp. 697-700, (1996).
	BT	The Condensed Chemical Dictionary, Fifth Edition, page 114 (1956).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.